1. Home
  2. SXTC vs GRI Comparison

SXTC vs GRI Comparison

Compare SXTC & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China SXT Pharmaceuticals Inc.

SXTC

China SXT Pharmaceuticals Inc.

HOLD

Current Price

$1.98

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.28

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTC
GRI
Founded
2005
2018
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
1.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SXTC
GRI
Price
$1.98
$2.28
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$644.00
AVG Volume (30 Days)
171.4K
112.0K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.18
52 Week High
$6.98
$11.12

Technical Indicators

Market Signals
Indicator
SXTC
GRI
Relative Strength Index (RSI) 48.74 50.21
Support Level $1.46 $2.10
Resistance Level $2.08 $2.65
Average True Range (ATR) 0.26 0.20
MACD -0.10 -0.07
Stochastic Oscillator 6.86 32.14

Price Performance

Historical Comparison
SXTC
GRI

About SXTC China SXT Pharmaceuticals Inc.

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: